Share Twitter LinkedIn Facebook Email Jesus Berdeja, MD @BerdejaJesus of Sarah Cannon Center for Blood Cancers discusses the phase 1 clinical study of bb21217.
53 vs 31 Month Isatuximab-VRD Results: My Interview with SANOFI’s Global Product Head at ASCO 2024 ASCO Annual Meeting 2 Mins Read
